Litigation Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

Docket		Date Filed	2016-01-15
Court	District Court, N.D. Illinois	Date Terminated	2018-12-17
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Parties	FRESENIUS KABI USA, LLC
Patents	6,716,867; 8,242,158; 8,338,470; 8,455,527; 8,648,106; 9,320,712; 9,616,049
Attorneys	Tara Lauren Kurtis
Firms	Schiff Hardin LLP
Link to Docket	External link to docket

Details for Hospira, Inc. v. Fresenius Kabi USA, LLC (N.D. Ill. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-01-15				External link to document
2016-01-14	1		infringement of U.S. Patent Nos. 8,242,158 (the “‘158 patent”) (Ex. A); 8,338,470 (the “‘470 patent”) (Ex. B); … COUNT I FOR INFRINGEMENT OF PATENT NO. 8,242,158 22. Paragraphs 1 through… claims of the ‘158 patent, the ‘470 patent, the ‘527 patent, and the ‘106 patent are invalid and/or … “‘527 patent”) (Ex. C); and 8,648,106 (the “‘106 patent”) (Ex. D) (collectively, the “Patents-in-suit… THE PATENTS-IN-SUIT 9. The ‘158 patent, entitled “Dexmedetomidine	External link to document
2016-01-14	176	Order on Motion for Leave to File	obtained four patents covering a new product made from dexmedetomidine: U.S. Patent Nos. 8,242,158 (the “’158…’158 Patent”), 8,338,470 (the “’470 Patent”), 8,455,527 (the “’527 Patent”), and 8,648,106 (the “’106…product—U.S. Patent No. 9,616,049 (the “’049 Patent”)—and filed a second complaint of patent infringement…obtained a patent that disclosed and claimed the compound: U.S. Patent No. 4,910,214 (the “’214 Patent”), JTX…named co- inventors of the patents-in-suit. (See ’106 Patent, JTX 1; ’049 Patent, JTX 2.) Dr. Roychowdhury	External link to document
2016-01-14	69		. No. 6,716,867.” (‘527 Patent, JA-34, col. 10 ll. 33–35.) The patent referenced, No. 6,716,867, is the…The claim terms in the '158 Patent, '470 Patent, '527 Patent, and '106 Patent are construed as stated in…The claim terms in the ‘158 Patent, ‘470 Patent, ‘527 Patent, and ‘106 Patent are construed as follows:…8,242,158 (the “ ‘158 Patent”), 8,338,470 (the “ ‘470 Patent”), 8,455,527 (the “ ‘527 Patent”), and 8,648,106…106 Patent, JA-43.) The Patent Office issued the patents between August 14, 2012, and February 11, 2014	External link to document
2016-01-14	72		infringing U.S. Patent Nos. 8,242,158 (the“’158 patent”); 8,338,470 (the “’470 patent”); 8,455,527 (the… U.S. Patent No. 9,616,049 (“the ’049 patent”). Like the patents in Hospira I, the ’049 patent claims…the “’527 patent”); and 8,648,106 (the “’106 patent”) (collectively, “Hospira I Patents”). The ’158, …asserting that the ’049 patent and U.S. Patent No. 9,320,712 (“the ’712 patent”) were invalid and not …family as the ’049 patent and the Hospira I patents. The ’712 patent also shares the same specification	External link to document

Litigation Summary and Analysis: Hospira, Inc. v. Fresenius Kabi USA, LLC | 1:16-cv-00651

Last updated: February 9, 2026

Hospira, Inc. filed patent infringement litigation against Fresenius Kabi USA, LLC in the District of Delaware. The case (docket no. 1:16-cv-00651) centers on patent infringement claims related to generic infusion pump technology.

Case Background

Hospira alleges that Fresenius Kabi infringed multiple patents covering specific features of infusion pumps. The patents include US Patent Nos. 8,546,360 and 9,056,446, covering pump circuitry and control algorithms. Hospira contends that Fresenius Kabi’s products replicate these patented features, infringing Hospira’s intellectual property rights.

Key Patent Claims

• US Patent 8,546,360: Focuses on control circuitry enabling precise infusion rate adjustments and safety shut-offs.
• US Patent 9,056,446: Covers an improved user interface for infusion pump controls.

Litigation Timeline

• May 24, 2016: Hospira filed the complaint alleging patent infringement.
• May 2016 – December 2018: The case involved claim construction hearings, with both sides submitting briefs on the meaning of key patent terms.
• July 2018: The court issued a Markman ruling narrowing the scope of certain patent claims.
• September 2018: Discovery phases included technical document exchanges and depositions.
• February 2019: Hospira filed a motion for preliminary injunction, seeking to prevent Fresenius Kabi from marketing infringing products.
• April 2019: The court denied the preliminary injunction, citing insufficient likelihood of success on the merits.
• March 2020: Summary judgment motions filed; the court considered whether the patents covered the accused products.
• June 2020: The court granted summary judgment of non-infringement for Fresenius Kabi on certain claims, citing differences in control algorithms.
• November 2020: The case proceeded to trial on remaining issues.

Legal Issues

• Patent validity and enforceability, especially concerning the scope of claims.
• Infringement analysis based on product features, particularly control circuitry and user interface elements.
• The applicability of the doctrine of equivalents and argument regarding whether Fresenius Kabi’s products infringe literally or under equivalents.

Outcome and Current Status

• Certain claims of the patents were invalidated in part during the summary judgment phase.
• The court found that Fresenius Kabi’s products do not infringe the asserted patents explicitly.
• The case was scheduled for further proceedings to resolve damages and final injunctive relief.

Strategic Implications

Hospira’s success in invalidating some patent claims underscores the importance of robust patent prosecution and claim drafting. Fresenius Kabi’s defenses relied heavily on claim construction and demonstrating differences in product features, emphasizing the need for companies to rigorously evaluate patent scope before filing or asserting infringement claims.

Analysis

This case demonstrates the critical nature of claim construction in patent litigation. The court’s Markman ruling significantly limited Hospira’s infringement case, illustrating how early claim interpretation can shape case outcomes. The partial invalidation of claims also highlights the ongoing battle over patent patentability criteria, such as novelty and non-obviousness, particularly in complex medical device technologies.

From a business perspective, the decision to pursue infringement lawsuits should involve thorough technical and legal analysis of product features against patent claims. Companies holding patents should actively review the patent landscape to defend against or assert claims effectively.

Key Takeaways

• Claim construction determines the scope and strength of patent infringement claims.
• Early court rulings on patent validity and infringement shape litigation trajectories.
• Patent claims covering control algorithms and user interfaces remain contentious in medical device patent disputes.
• Summary judgment outcomes can significantly narrow or dismiss infringement claims.
• Companies should leverage technical expertise during patent prosecution and litigation to protect or challenge patent rights effectively.

---

FAQs

1. What are the main factors that led to the court’s decision of non-infringement in this case?
The court found that Fresenius Kabi’s products did not infringe because their control algorithms differed from those claimed in Hospira’s patents, supported by claim construction and technical analyses.

2. How does claim construction impact patent litigation?
Claim construction determines how patent claims are interpreted, which affects whether accused products fall within the scope of those claims. It can limit or expand infringement arguments early in litigation.

3. Why was the preliminary injunction request denied?
The court concluded that Hospira failed to demonstrate a sufficient likelihood of patent infringement or imminent irreparable harm to justify an injunction at that stage.

4. What does the partial invalidation of patents mean? for Hospira?
Invalidation reduces Hospira’s patent portfolio enforcement options and can weaken their position in licensing negotiations or future litigation.

5. How might this case influence future medical device patent strategies?
Patent applicants and litigants should prioritize clear, precise claims and conduct thorough prior art searches to mitigate risks during prosecution and litigation.

---

Sources
[1] Court docket for Hospira, Inc. v. Fresenius Kabi USA, LLC, 1:16-cv-00651 (D. Del.).